Physician profile
Beverly Wright
NPI 1639165137
$2,299.12
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,234 · 2023: $869 · 2024: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,066.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,065.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $492.71 | 2022-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $312.98 | 2022-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $296.98 | 2022-2023 | Azstarys |
| Abbvie INC. | $239.03 | 2022 | |
| Neurocrine Biosciences, INC. | $218.55 | 2022-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $185.84 | 2022-2024 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $146.97 | 2022 | |
| Genentech USA, INC. | $121.32 | 2023 | Vabysmo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.83 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $63.30 | 2022-2024 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $54.05 | 2024 | Auvelity |
| Lundbeck LLC | $29.02 | 2023-2024 | Rexulti |
| Indivior INC. | $17.54 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.